

Special Issue

Advances in Precision Diagnostics and Personalized Therapeutics for Prostate Cancer

Message from the Guest Editor

This Special Issue will highlight state-of-the-art advances in prostate cancer, from precision diagnostics to personalized treatment. We welcome original research articles and authoritative reviews exploring screening and risk stratification, imaging and biomarkers (including molecular and AI-assisted approaches), pathology and genomics, and clinical decision tools. Therapeutic topics of interest include surgery, radiotherapy, systemic therapy (hormonal therapy, chemotherapy, targeted therapy, radioligand therapy, and immunotherapy), and focal therapies, as well as treatment sequencing, real-world outcomes, and the management of adverse events. Submissions addressing diverse patient populations and translational innovations are especially encouraged.

Guest Editor

Dr. Takanobu Utsumi

Urology and Director of the Clinical Genetics Center, Toho University
Sakura Medical Center, Sakura, Japan

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/266921

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)